Global T-Cell Immunotherapy

T-Cell Immunotherapy Comprehensive Study by Type (Active Immunotherapy, Passive Immunotherapy), Application (Stomach Cancer, Lung Cancer, Colorectal Cancer, Esophagus Cancer, Pancreatic Cancer, Others), Modility (Research, Commercialized), Product Class (Monoclonal Antibodies, Oncolytic Virus Therapy, Bispecific Antibodies, Cytokines), Indication (Hematologic Malignancies (Lymphoma, Leukemia, Myeloma), Solid Tumors (Melanoma, Brain & Central Nervous System, Liver Cancer, Others)), Therapy Type (CAR T-cell Therapy, T Cell Receptor (TCR)-based, Tumor-Infiltrating Lymphocytes (TIL)-based), End User (Hospitals, Cancer Research Centers, Clinics) Players and Region - Global Market Outlook to 2030

T-Cell Immunotherapy Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 16.42%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About T-Cell Immunotherapy
The global T-cell Immunotherapy market is expected to boost the global demand in the forecasted period due to the growing demand for better cancer treatment in cancer in children is escalating the growth of the T-cell immunotherapy market. T-Cell Immunotherapy is a type of treatment in which a patient’s T cells (a type of immune cell) are changed in the laboratory so they will bind to cancer cells and kill them. The global and regional prevalence of major types of cancer for which T-cell Immunotherapy is used is highlighted in the report. These cancers include leukemia, lymphoma, melanoma, ovarian cancer, and bladder cancer amongst others.

AttributesDetails
Study Period2019-2030
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Million)
CAGR16.42%


With the approval of Kymriah and Yescarta, several companies have shifted their business models from developing small molecule and protein-based therapies to adoptive T cell therapy. A range of market entities, from new entrants to the well-established pharma companies are exploring the therapy, which is anticipated to intensify the competition as multiple companies are receiving approvals and consequently gearing up their manufacturing capabilities. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global T-Cell Immunotherapy market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novartis AG (Switzerland), Gilead Sciences (United States), bluebird bio (United States), TCR2 Therapeutics Inc. (United States), Sorrento Therapeutics (United States), Fate Therapeutics (United States), Merck KGaA (Germany), Pfizer (United States) and Amgen (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Adaptimmune Therapeutices (United Kingdom), Alaunos Therapeutics (United States) and Autolus Therapeutics (United States).

Segmentation Overview
AMA Research has segmented the market of Global T-Cell Immunotherapy market by Type (Active Immunotherapy and Passive Immunotherapy), Application (Stomach Cancer, Lung Cancer, Colorectal Cancer, Esophagus Cancer, Pancreatic Cancer and Others) and Region.



On the basis of geography, the market of T-Cell Immunotherapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by Modility, the sub-segment i.e. Research will boost the T-Cell Immunotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Product Class, the sub-segment i.e. Monoclonal Antibodies will boost the T-Cell Immunotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indication, the sub-segment i.e. Hematologic Malignancies [Lymphoma, Leukemia, Myeloma] will boost the T-Cell Immunotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapy Type, the sub-segment i.e. CAR T-cell Therapy will boost the T-Cell Immunotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the T-Cell Immunotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Network of Diverse CAR-T/TCR Developers with Their Offerings would Reshape the Engineered T cells Market Landscape and The Rising Preference for the Gene Therapies in the Cancer Treatment

Market Growth Drivers:
High Demand due to Clinical Success and Accelerated Product Approvals and The Growing Prevalence of Cancer

Challenges:
The Stringent Government Regulation associated with T-Cell Immunotherapy

Restraints:
The Rising Concern with The Side Effects

Opportunities:
Increasing Investments by Government Bodies and Growing Technological Advancements in the field of Immunotherapy

Market Leaders and their expansionary development strategies
In June 2023, Johnson & Johnson partners with Umoja Biopharma to develop a next-generation CD19 CAR-T therapy for B-cell malignancies. the Johnson & Johnson-Umoja Biopharma partnership marks a significant advancement in the field of CAR-T therapy for B-cell malignancies. This collaboration has the potential to revolutionize cancer treatment by making it more accessible, effective, and affordable for patients in need.
In November 2023, Adaptimmune launches afnitamab for the treatment of certain types of B-cell lymphomas in Europe. The launch of afnitamab represents a significant step forward in the treatment of B-cell lymphomas in Europe. It offers a potentially curative option for patients with relapsed or refractory disease, although challenges related to access, and potential side effects must be addressed.
Tocilizumab (Actemra®) is approved for the treatment of adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS). and Tisagenlecleucel (KymriahTM) is FDA approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Kymriah is also approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Key Target Audience
T-Cell Immunotherapy Providers, Government Regulatory Bodies, Private Research Organizations, Government Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Active Immunotherapy
  • Passive Immunotherapy
By Application
  • Stomach Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Esophagus Cancer
  • Pancreatic Cancer
  • Others
By Modility
  • Research
  • Commercialized

By Product Class
  • Monoclonal Antibodies
  • Oncolytic Virus Therapy
  • Bispecific Antibodies
  • Cytokines

By Indication
  • Hematologic Malignancies [Lymphoma, Leukemia, Myeloma]
  • Solid Tumors [Melanoma, Brain & Central Nervous System, Liver Cancer, Others]

By Therapy Type
  • CAR T-cell Therapy
  • T Cell Receptor (TCR)-based
  • Tumor-Infiltrating Lymphocytes (TIL)-based

By End User
  • Hospitals
  • Cancer Research Centers
  • Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Demand due to Clinical Success and Accelerated Product Approvals
      • 3.2.2. The Growing Prevalence of Cancer
    • 3.3. Market Challenges
      • 3.3.1. The Stringent Government Regulation associated with T-Cell Immunotherapy
    • 3.4. Market Trends
      • 3.4.1. Growing Network of Diverse CAR-T/TCR Developers with Their Offerings would Reshape the Engineered T cells Market Landscape
      • 3.4.2. The Rising Preference for the Gene Therapies in the Cancer Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global T-Cell Immunotherapy, by Type, Application, Modility, Product Class, Indication, Therapy Type, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global T-Cell Immunotherapy (Value)
      • 5.2.1. Global T-Cell Immunotherapy by: Type (Value)
        • 5.2.1.1. Active Immunotherapy
        • 5.2.1.2. Passive Immunotherapy
      • 5.2.2. Global T-Cell Immunotherapy by: Application (Value)
        • 5.2.2.1. Stomach Cancer
        • 5.2.2.2. Lung Cancer
        • 5.2.2.3. Colorectal Cancer
        • 5.2.2.4. Esophagus Cancer
        • 5.2.2.5. Pancreatic Cancer
        • 5.2.2.6. Others
      • 5.2.3. Global T-Cell Immunotherapy by: Modility (Value)
        • 5.2.3.1. Research
        • 5.2.3.2. Commercialized
      • 5.2.4. Global T-Cell Immunotherapy by: Product Class (Value)
        • 5.2.4.1. Monoclonal Antibodies
        • 5.2.4.2. Oncolytic Virus Therapy
        • 5.2.4.3. Bispecific Antibodies
        • 5.2.4.4. Cytokines
      • 5.2.5. Global T-Cell Immunotherapy by: Indication (Value)
        • 5.2.5.1. Hematologic Malignancies [Lymphoma, Leukemia, Myeloma]
        • 5.2.5.2. Solid Tumors [Melanoma, Brain & Central Nervous System, Liver Cancer, Others]
      • 5.2.6. Global T-Cell Immunotherapy by: Therapy Type (Value)
        • 5.2.6.1. CAR T-cell Therapy
        • 5.2.6.2. T Cell Receptor (TCR)-based
        • 5.2.6.3. Tumor-Infiltrating Lymphocytes (TIL)-based
      • 5.2.7. Global T-Cell Immunotherapy by: End User (Value)
        • 5.2.7.1. Hospitals
        • 5.2.7.2. Cancer Research Centers
        • 5.2.7.3. Clinics
      • 5.2.8. Global T-Cell Immunotherapy Region
        • 5.2.8.1. South America
          • 5.2.8.1.1. Brazil
          • 5.2.8.1.2. Argentina
          • 5.2.8.1.3. Rest of South America
        • 5.2.8.2. Asia Pacific
          • 5.2.8.2.1. China
          • 5.2.8.2.2. Japan
          • 5.2.8.2.3. India
          • 5.2.8.2.4. South Korea
          • 5.2.8.2.5. Taiwan
          • 5.2.8.2.6. Australia
          • 5.2.8.2.7. Rest of Asia-Pacific
        • 5.2.8.3. Europe
          • 5.2.8.3.1. Germany
          • 5.2.8.3.2. France
          • 5.2.8.3.3. Italy
          • 5.2.8.3.4. United Kingdom
          • 5.2.8.3.5. Netherlands
          • 5.2.8.3.6. Rest of Europe
        • 5.2.8.4. MEA
          • 5.2.8.4.1. Middle East
          • 5.2.8.4.2. Africa
        • 5.2.8.5. North America
          • 5.2.8.5.1. United States
          • 5.2.8.5.2. Canada
          • 5.2.8.5.3. Mexico
    • 5.3. Global T-Cell Immunotherapy (Price)
      • 5.3.1. Global T-Cell Immunotherapy by: Type (Price)
  • 6. T-Cell Immunotherapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Gilead Sciences (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bluebird bio (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. TCR2 Therapeutics Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sorrento Therapeutics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Fate Therapeutics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck KGaA (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Amgen (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global T-Cell Immunotherapy Sale, by Type, Application, Modility, Product Class, Indication, Therapy Type, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global T-Cell Immunotherapy (Value)
      • 7.2.1. Global T-Cell Immunotherapy by: Type (Value)
        • 7.2.1.1. Active Immunotherapy
        • 7.2.1.2. Passive Immunotherapy
      • 7.2.2. Global T-Cell Immunotherapy by: Application (Value)
        • 7.2.2.1. Stomach Cancer
        • 7.2.2.2. Lung Cancer
        • 7.2.2.3. Colorectal Cancer
        • 7.2.2.4. Esophagus Cancer
        • 7.2.2.5. Pancreatic Cancer
        • 7.2.2.6. Others
      • 7.2.3. Global T-Cell Immunotherapy by: Modility (Value)
        • 7.2.3.1. Research
        • 7.2.3.2. Commercialized
      • 7.2.4. Global T-Cell Immunotherapy by: Product Class (Value)
        • 7.2.4.1. Monoclonal Antibodies
        • 7.2.4.2. Oncolytic Virus Therapy
        • 7.2.4.3. Bispecific Antibodies
        • 7.2.4.4. Cytokines
      • 7.2.5. Global T-Cell Immunotherapy by: Indication (Value)
        • 7.2.5.1. Hematologic Malignancies [Lymphoma, Leukemia, Myeloma]
        • 7.2.5.2. Solid Tumors [Melanoma, Brain & Central Nervous System, Liver Cancer, Others]
      • 7.2.6. Global T-Cell Immunotherapy by: Therapy Type (Value)
        • 7.2.6.1. CAR T-cell Therapy
        • 7.2.6.2. T Cell Receptor (TCR)-based
        • 7.2.6.3. Tumor-Infiltrating Lymphocytes (TIL)-based
      • 7.2.7. Global T-Cell Immunotherapy by: End User (Value)
        • 7.2.7.1. Hospitals
        • 7.2.7.2. Cancer Research Centers
        • 7.2.7.3. Clinics
      • 7.2.8. Global T-Cell Immunotherapy Region
        • 7.2.8.1. South America
          • 7.2.8.1.1. Brazil
          • 7.2.8.1.2. Argentina
          • 7.2.8.1.3. Rest of South America
        • 7.2.8.2. Asia Pacific
          • 7.2.8.2.1. China
          • 7.2.8.2.2. Japan
          • 7.2.8.2.3. India
          • 7.2.8.2.4. South Korea
          • 7.2.8.2.5. Taiwan
          • 7.2.8.2.6. Australia
          • 7.2.8.2.7. Rest of Asia-Pacific
        • 7.2.8.3. Europe
          • 7.2.8.3.1. Germany
          • 7.2.8.3.2. France
          • 7.2.8.3.3. Italy
          • 7.2.8.3.4. United Kingdom
          • 7.2.8.3.5. Netherlands
          • 7.2.8.3.6. Rest of Europe
        • 7.2.8.4. MEA
          • 7.2.8.4.1. Middle East
          • 7.2.8.4.2. Africa
        • 7.2.8.5. North America
          • 7.2.8.5.1. United States
          • 7.2.8.5.2. Canada
          • 7.2.8.5.3. Mexico
    • 7.3. Global T-Cell Immunotherapy (Price)
      • 7.3.1. Global T-Cell Immunotherapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. T-Cell Immunotherapy: by Type(USD Million)
  • Table 2. T-Cell Immunotherapy Active Immunotherapy , by Region USD Million (2018-2023)
  • Table 3. T-Cell Immunotherapy Passive Immunotherapy , by Region USD Million (2018-2023)
  • Table 4. T-Cell Immunotherapy: by Application(USD Million)
  • Table 5. T-Cell Immunotherapy Stomach Cancer , by Region USD Million (2018-2023)
  • Table 6. T-Cell Immunotherapy Lung Cancer , by Region USD Million (2018-2023)
  • Table 7. T-Cell Immunotherapy Colorectal Cancer , by Region USD Million (2018-2023)
  • Table 8. T-Cell Immunotherapy Esophagus Cancer , by Region USD Million (2018-2023)
  • Table 9. T-Cell Immunotherapy Pancreatic Cancer , by Region USD Million (2018-2023)
  • Table 10. T-Cell Immunotherapy Others , by Region USD Million (2018-2023)
  • Table 11. T-Cell Immunotherapy: by Modility(USD Million)
  • Table 12. T-Cell Immunotherapy Research , by Region USD Million (2018-2023)
  • Table 13. T-Cell Immunotherapy Commercialized , by Region USD Million (2018-2023)
  • Table 14. T-Cell Immunotherapy: by Product Class(USD Million)
  • Table 15. T-Cell Immunotherapy Monoclonal Antibodies , by Region USD Million (2018-2023)
  • Table 16. T-Cell Immunotherapy Oncolytic Virus Therapy , by Region USD Million (2018-2023)
  • Table 17. T-Cell Immunotherapy Bispecific Antibodies , by Region USD Million (2018-2023)
  • Table 18. T-Cell Immunotherapy Cytokines , by Region USD Million (2018-2023)
  • Table 19. T-Cell Immunotherapy: by Indication(USD Million)
  • Table 20. T-Cell Immunotherapy Hematologic Malignancies [Lymphoma, Leukemia, Myeloma] , by Region USD Million (2018-2023)
  • Table 21. T-Cell Immunotherapy Solid Tumors [Melanoma, Brain & Central Nervous System, Liver Cancer, Others] , by Region USD Million (2018-2023)
  • Table 22. T-Cell Immunotherapy: by Therapy Type(USD Million)
  • Table 23. T-Cell Immunotherapy CAR T-cell Therapy , by Region USD Million (2018-2023)
  • Table 24. T-Cell Immunotherapy T Cell Receptor (TCR)-based , by Region USD Million (2018-2023)
  • Table 25. T-Cell Immunotherapy Tumor-Infiltrating Lymphocytes (TIL)-based , by Region USD Million (2018-2023)
  • Table 26. T-Cell Immunotherapy: by End User(USD Million)
  • Table 27. T-Cell Immunotherapy Hospitals , by Region USD Million (2018-2023)
  • Table 28. T-Cell Immunotherapy Cancer Research Centers , by Region USD Million (2018-2023)
  • Table 29. T-Cell Immunotherapy Clinics , by Region USD Million (2018-2023)
  • Table 30. South America T-Cell Immunotherapy, by Country USD Million (2018-2023)
  • Table 31. South America T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 32. South America T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 33. South America T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 34. South America T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 35. South America T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 36. South America T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 37. South America T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 38. Brazil T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 39. Brazil T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 40. Brazil T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 41. Brazil T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 42. Brazil T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 43. Brazil T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 44. Brazil T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 45. Argentina T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 46. Argentina T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 47. Argentina T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 48. Argentina T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 49. Argentina T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 50. Argentina T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 51. Argentina T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 52. Rest of South America T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 53. Rest of South America T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 54. Rest of South America T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 55. Rest of South America T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 56. Rest of South America T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 57. Rest of South America T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 58. Rest of South America T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 59. Asia Pacific T-Cell Immunotherapy, by Country USD Million (2018-2023)
  • Table 60. Asia Pacific T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 61. Asia Pacific T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 62. Asia Pacific T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 63. Asia Pacific T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 64. Asia Pacific T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 65. Asia Pacific T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 66. Asia Pacific T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 67. China T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 68. China T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 69. China T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 70. China T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 71. China T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 72. China T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 73. China T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 74. Japan T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 75. Japan T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 76. Japan T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 77. Japan T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 78. Japan T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 79. Japan T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 80. Japan T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 81. India T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 82. India T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 83. India T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 84. India T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 85. India T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 86. India T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 87. India T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 88. South Korea T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 89. South Korea T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 90. South Korea T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 91. South Korea T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 92. South Korea T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 93. South Korea T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 94. South Korea T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 95. Taiwan T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 96. Taiwan T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 97. Taiwan T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 98. Taiwan T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 99. Taiwan T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 100. Taiwan T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 101. Taiwan T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 102. Australia T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 103. Australia T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 104. Australia T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 105. Australia T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 106. Australia T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 107. Australia T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 108. Australia T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 109. Rest of Asia-Pacific T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 110. Rest of Asia-Pacific T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 111. Rest of Asia-Pacific T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 112. Rest of Asia-Pacific T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 113. Rest of Asia-Pacific T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 114. Rest of Asia-Pacific T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 115. Rest of Asia-Pacific T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 116. Europe T-Cell Immunotherapy, by Country USD Million (2018-2023)
  • Table 117. Europe T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 118. Europe T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 119. Europe T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 120. Europe T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 121. Europe T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 122. Europe T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 123. Europe T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 124. Germany T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 125. Germany T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 126. Germany T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 127. Germany T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 128. Germany T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 129. Germany T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 130. Germany T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 131. France T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 132. France T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 133. France T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 134. France T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 135. France T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 136. France T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 137. France T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 138. Italy T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 139. Italy T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 140. Italy T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 141. Italy T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 142. Italy T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 143. Italy T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 144. Italy T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 145. United Kingdom T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 146. United Kingdom T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 147. United Kingdom T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 148. United Kingdom T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 149. United Kingdom T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 150. United Kingdom T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 151. United Kingdom T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 152. Netherlands T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 153. Netherlands T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 154. Netherlands T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 155. Netherlands T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 156. Netherlands T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 157. Netherlands T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 158. Netherlands T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 159. Rest of Europe T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 160. Rest of Europe T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 161. Rest of Europe T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 162. Rest of Europe T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 163. Rest of Europe T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 164. Rest of Europe T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 165. Rest of Europe T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 166. MEA T-Cell Immunotherapy, by Country USD Million (2018-2023)
  • Table 167. MEA T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 168. MEA T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 169. MEA T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 170. MEA T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 171. MEA T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 172. MEA T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 173. MEA T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 174. Middle East T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 175. Middle East T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 176. Middle East T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 177. Middle East T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 178. Middle East T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 179. Middle East T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 180. Middle East T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 181. Africa T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 182. Africa T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 183. Africa T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 184. Africa T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 185. Africa T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 186. Africa T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 187. Africa T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 188. North America T-Cell Immunotherapy, by Country USD Million (2018-2023)
  • Table 189. North America T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 190. North America T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 191. North America T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 192. North America T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 193. North America T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 194. North America T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 195. North America T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 196. United States T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 197. United States T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 198. United States T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 199. United States T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 200. United States T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 201. United States T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 202. United States T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 203. Canada T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 204. Canada T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 205. Canada T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 206. Canada T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 207. Canada T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 208. Canada T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 209. Canada T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 210. Mexico T-Cell Immunotherapy, by Type USD Million (2018-2023)
  • Table 211. Mexico T-Cell Immunotherapy, by Application USD Million (2018-2023)
  • Table 212. Mexico T-Cell Immunotherapy, by Modility USD Million (2018-2023)
  • Table 213. Mexico T-Cell Immunotherapy, by Product Class USD Million (2018-2023)
  • Table 214. Mexico T-Cell Immunotherapy, by Indication USD Million (2018-2023)
  • Table 215. Mexico T-Cell Immunotherapy, by Therapy Type USD Million (2018-2023)
  • Table 216. Mexico T-Cell Immunotherapy, by End User USD Million (2018-2023)
  • Table 217. T-Cell Immunotherapy: by Type(USD/Units)
  • Table 218. Company Basic Information, Sales Area and Its Competitors
  • Table 219. Company Basic Information, Sales Area and Its Competitors
  • Table 220. Company Basic Information, Sales Area and Its Competitors
  • Table 221. Company Basic Information, Sales Area and Its Competitors
  • Table 222. Company Basic Information, Sales Area and Its Competitors
  • Table 223. Company Basic Information, Sales Area and Its Competitors
  • Table 224. Company Basic Information, Sales Area and Its Competitors
  • Table 225. Company Basic Information, Sales Area and Its Competitors
  • Table 226. Company Basic Information, Sales Area and Its Competitors
  • Table 227. T-Cell Immunotherapy: by Type(USD Million)
  • Table 228. T-Cell Immunotherapy Active Immunotherapy , by Region USD Million (2025-2030)
  • Table 229. T-Cell Immunotherapy Passive Immunotherapy , by Region USD Million (2025-2030)
  • Table 230. T-Cell Immunotherapy: by Application(USD Million)
  • Table 231. T-Cell Immunotherapy Stomach Cancer , by Region USD Million (2025-2030)
  • Table 232. T-Cell Immunotherapy Lung Cancer , by Region USD Million (2025-2030)
  • Table 233. T-Cell Immunotherapy Colorectal Cancer , by Region USD Million (2025-2030)
  • Table 234. T-Cell Immunotherapy Esophagus Cancer , by Region USD Million (2025-2030)
  • Table 235. T-Cell Immunotherapy Pancreatic Cancer , by Region USD Million (2025-2030)
  • Table 236. T-Cell Immunotherapy Others , by Region USD Million (2025-2030)
  • Table 237. T-Cell Immunotherapy: by Modility(USD Million)
  • Table 238. T-Cell Immunotherapy Research , by Region USD Million (2025-2030)
  • Table 239. T-Cell Immunotherapy Commercialized , by Region USD Million (2025-2030)
  • Table 240. T-Cell Immunotherapy: by Product Class(USD Million)
  • Table 241. T-Cell Immunotherapy Monoclonal Antibodies , by Region USD Million (2025-2030)
  • Table 242. T-Cell Immunotherapy Oncolytic Virus Therapy , by Region USD Million (2025-2030)
  • Table 243. T-Cell Immunotherapy Bispecific Antibodies , by Region USD Million (2025-2030)
  • Table 244. T-Cell Immunotherapy Cytokines , by Region USD Million (2025-2030)
  • Table 245. T-Cell Immunotherapy: by Indication(USD Million)
  • Table 246. T-Cell Immunotherapy Hematologic Malignancies [Lymphoma, Leukemia, Myeloma] , by Region USD Million (2025-2030)
  • Table 247. T-Cell Immunotherapy Solid Tumors [Melanoma, Brain & Central Nervous System, Liver Cancer, Others] , by Region USD Million (2025-2030)
  • Table 248. T-Cell Immunotherapy: by Therapy Type(USD Million)
  • Table 249. T-Cell Immunotherapy CAR T-cell Therapy , by Region USD Million (2025-2030)
  • Table 250. T-Cell Immunotherapy T Cell Receptor (TCR)-based , by Region USD Million (2025-2030)
  • Table 251. T-Cell Immunotherapy Tumor-Infiltrating Lymphocytes (TIL)-based , by Region USD Million (2025-2030)
  • Table 252. T-Cell Immunotherapy: by End User(USD Million)
  • Table 253. T-Cell Immunotherapy Hospitals , by Region USD Million (2025-2030)
  • Table 254. T-Cell Immunotherapy Cancer Research Centers , by Region USD Million (2025-2030)
  • Table 255. T-Cell Immunotherapy Clinics , by Region USD Million (2025-2030)
  • Table 256. South America T-Cell Immunotherapy, by Country USD Million (2025-2030)
  • Table 257. South America T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 258. South America T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 259. South America T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 260. South America T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 261. South America T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 262. South America T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 263. South America T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 264. Brazil T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 265. Brazil T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 266. Brazil T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 267. Brazil T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 268. Brazil T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 269. Brazil T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 270. Brazil T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 271. Argentina T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 272. Argentina T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 273. Argentina T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 274. Argentina T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 275. Argentina T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 276. Argentina T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 277. Argentina T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 278. Rest of South America T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 279. Rest of South America T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 280. Rest of South America T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 281. Rest of South America T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 282. Rest of South America T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 283. Rest of South America T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 284. Rest of South America T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 285. Asia Pacific T-Cell Immunotherapy, by Country USD Million (2025-2030)
  • Table 286. Asia Pacific T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 287. Asia Pacific T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 288. Asia Pacific T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 289. Asia Pacific T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 290. Asia Pacific T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 291. Asia Pacific T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 292. Asia Pacific T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 293. China T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 294. China T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 295. China T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 296. China T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 297. China T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 298. China T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 299. China T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 300. Japan T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 301. Japan T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 302. Japan T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 303. Japan T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 304. Japan T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 305. Japan T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 306. Japan T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 307. India T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 308. India T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 309. India T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 310. India T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 311. India T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 312. India T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 313. India T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 314. South Korea T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 315. South Korea T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 316. South Korea T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 317. South Korea T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 318. South Korea T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 319. South Korea T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 320. South Korea T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 321. Taiwan T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 322. Taiwan T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 323. Taiwan T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 324. Taiwan T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 325. Taiwan T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 326. Taiwan T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 327. Taiwan T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 328. Australia T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 329. Australia T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 330. Australia T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 331. Australia T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 332. Australia T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 333. Australia T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 334. Australia T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 335. Rest of Asia-Pacific T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 336. Rest of Asia-Pacific T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 337. Rest of Asia-Pacific T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 338. Rest of Asia-Pacific T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 339. Rest of Asia-Pacific T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 340. Rest of Asia-Pacific T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 341. Rest of Asia-Pacific T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 342. Europe T-Cell Immunotherapy, by Country USD Million (2025-2030)
  • Table 343. Europe T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 344. Europe T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 345. Europe T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 346. Europe T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 347. Europe T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 348. Europe T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 349. Europe T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 350. Germany T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 351. Germany T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 352. Germany T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 353. Germany T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 354. Germany T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 355. Germany T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 356. Germany T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 357. France T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 358. France T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 359. France T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 360. France T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 361. France T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 362. France T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 363. France T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 364. Italy T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 365. Italy T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 366. Italy T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 367. Italy T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 368. Italy T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 369. Italy T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 370. Italy T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 371. United Kingdom T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 372. United Kingdom T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 373. United Kingdom T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 374. United Kingdom T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 375. United Kingdom T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 376. United Kingdom T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 377. United Kingdom T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 378. Netherlands T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 379. Netherlands T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 380. Netherlands T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 381. Netherlands T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 382. Netherlands T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 383. Netherlands T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 384. Netherlands T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 385. Rest of Europe T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 386. Rest of Europe T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 387. Rest of Europe T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 388. Rest of Europe T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 389. Rest of Europe T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 390. Rest of Europe T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 391. Rest of Europe T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 392. MEA T-Cell Immunotherapy, by Country USD Million (2025-2030)
  • Table 393. MEA T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 394. MEA T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 395. MEA T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 396. MEA T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 397. MEA T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 398. MEA T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 399. MEA T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 400. Middle East T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 401. Middle East T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 402. Middle East T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 403. Middle East T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 404. Middle East T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 405. Middle East T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 406. Middle East T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 407. Africa T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 408. Africa T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 409. Africa T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 410. Africa T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 411. Africa T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 412. Africa T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 413. Africa T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 414. North America T-Cell Immunotherapy, by Country USD Million (2025-2030)
  • Table 415. North America T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 416. North America T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 417. North America T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 418. North America T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 419. North America T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 420. North America T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 421. North America T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 422. United States T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 423. United States T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 424. United States T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 425. United States T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 426. United States T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 427. United States T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 428. United States T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 429. Canada T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 430. Canada T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 431. Canada T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 432. Canada T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 433. Canada T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 434. Canada T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 435. Canada T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 436. Mexico T-Cell Immunotherapy, by Type USD Million (2025-2030)
  • Table 437. Mexico T-Cell Immunotherapy, by Application USD Million (2025-2030)
  • Table 438. Mexico T-Cell Immunotherapy, by Modility USD Million (2025-2030)
  • Table 439. Mexico T-Cell Immunotherapy, by Product Class USD Million (2025-2030)
  • Table 440. Mexico T-Cell Immunotherapy, by Indication USD Million (2025-2030)
  • Table 441. Mexico T-Cell Immunotherapy, by Therapy Type USD Million (2025-2030)
  • Table 442. Mexico T-Cell Immunotherapy, by End User USD Million (2025-2030)
  • Table 443. T-Cell Immunotherapy: by Type(USD/Units)
  • Table 444. Research Programs/Design for This Report
  • Table 445. Key Data Information from Secondary Sources
  • Table 446. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global T-Cell Immunotherapy: by Type USD Million (2018-2023)
  • Figure 5. Global T-Cell Immunotherapy: by Application USD Million (2018-2023)
  • Figure 6. Global T-Cell Immunotherapy: by Modility USD Million (2018-2023)
  • Figure 7. Global T-Cell Immunotherapy: by Product Class USD Million (2018-2023)
  • Figure 8. Global T-Cell Immunotherapy: by Indication USD Million (2018-2023)
  • Figure 9. Global T-Cell Immunotherapy: by Therapy Type USD Million (2018-2023)
  • Figure 10. Global T-Cell Immunotherapy: by End User USD Million (2018-2023)
  • Figure 11. South America T-Cell Immunotherapy Share (%), by Country
  • Figure 12. Asia Pacific T-Cell Immunotherapy Share (%), by Country
  • Figure 13. Europe T-Cell Immunotherapy Share (%), by Country
  • Figure 14. MEA T-Cell Immunotherapy Share (%), by Country
  • Figure 15. North America T-Cell Immunotherapy Share (%), by Country
  • Figure 16. Global T-Cell Immunotherapy: by Type USD/Units (2018-2023)
  • Figure 17. Global T-Cell Immunotherapy share by Players 2023 (%)
  • Figure 18. Global T-Cell Immunotherapy share by Players (Top 3) 2023(%)
  • Figure 19. Global T-Cell Immunotherapy share by Players (Top 5) 2023(%)
  • Figure 20. BCG Matrix for key Companies
  • Figure 21. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 23. Gilead Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 24. Gilead Sciences (United States) Revenue: by Geography 2023
  • Figure 25. Bluebird bio (United States) Revenue, Net Income and Gross profit
  • Figure 26. Bluebird bio (United States) Revenue: by Geography 2023
  • Figure 27. TCR2 Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. TCR2 Therapeutics Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Sorrento Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 30. Sorrento Therapeutics (United States) Revenue: by Geography 2023
  • Figure 31. Fate Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 32. Fate Therapeutics (United States) Revenue: by Geography 2023
  • Figure 33. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 35. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer (United States) Revenue: by Geography 2023
  • Figure 37. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 38. Amgen (United States) Revenue: by Geography 2023
  • Figure 39. Global T-Cell Immunotherapy: by Type USD Million (2025-2030)
  • Figure 40. Global T-Cell Immunotherapy: by Application USD Million (2025-2030)
  • Figure 41. Global T-Cell Immunotherapy: by Modility USD Million (2025-2030)
  • Figure 42. Global T-Cell Immunotherapy: by Product Class USD Million (2025-2030)
  • Figure 43. Global T-Cell Immunotherapy: by Indication USD Million (2025-2030)
  • Figure 44. Global T-Cell Immunotherapy: by Therapy Type USD Million (2025-2030)
  • Figure 45. Global T-Cell Immunotherapy: by End User USD Million (2025-2030)
  • Figure 46. South America T-Cell Immunotherapy Share (%), by Country
  • Figure 47. Asia Pacific T-Cell Immunotherapy Share (%), by Country
  • Figure 48. Europe T-Cell Immunotherapy Share (%), by Country
  • Figure 49. MEA T-Cell Immunotherapy Share (%), by Country
  • Figure 50. North America T-Cell Immunotherapy Share (%), by Country
  • Figure 51. Global T-Cell Immunotherapy: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Novartis AG (Switzerland)
  • Gilead Sciences (United States)
  • bluebird bio (United States)
  • TCR2 Therapeutics Inc. (United States)
  • Sorrento Therapeutics (United States)
  • Fate Therapeutics (United States)
  • Merck KGaA (Germany)
  • Pfizer (United States)
  • Amgen (United States)
Additional players considered in the study are as follows:
Adaptimmune Therapeutices (United Kingdom) , Alaunos Therapeutics (United States) , Autolus Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 208 Pages 55 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global T-Cell Immunotherapy Quantitative research analysis
Global T-Cell Immunotherapy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Novartis AG (Switzerland), Gilead Sciences (United States), bluebird bio (United States), TCR2 Therapeutics Inc. (United States), Sorrento Therapeutics (United States), Fate Therapeutics (United States), Merck KGaA (Germany), Pfizer (United States) and Amgen (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Network of Diverse CAR-T/TCR Developers with Their Offerings would Reshape the Engineered T cells Market Landscape " is seen as one of major influencing trends for T-Cell Immunotherapy Market during projected period 2023-2030.
The T-Cell Immunotherapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global T-Cell Immunotherapy Report?

Have a Query? Click Here

Other Related Reports

Malaria Diagnostics Comprehensive Study by Type (Microscopy, Rapid Diagnostic Tests, Molecular Diagnostic Tests (Conventional PCR, Real-Time PCR (quantitative PCR or qPCR))), End User (Clinics, Hospi...
$ 3350
Minimally Invasive Surgery Comprehensive Study by Type (Endoscopic Devices, Electrosurgical Devices, Monitoring and Visualization Devices), Application (Cosmetic Surgery, Cardiac Surgery, Gastrointes...
$ 3650
Therapeutic Drug Monitoring Comprehensive Study by Type (Consumable, Equipment (Immunoassay analyzer)), Application (Hospitals (Clinical Pharmacology departments), Pathological labs, Research and Aca...
$ 3750
Digital Therapeutics Comprehensive Study by Disease (Diabetes, Obesity, Cardiovascular Diseases (CVD), Central Nervous System (CNS) Disease, Gastrointestinal Disorders (GID), Respiratory Diseases, Sm...
$ 3650
Kidney Fibrosis Treatment Comprehensive Study by Therapeutics (Angiotensin Converting Enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasopeptidase In...
$ 3350
Legionella Testing Comprehensive Study by Type (Microbial Culture, DFA Stain, PCR, Others), Application (Water Testing, IVD Testing), End User (Hospital and Clinic, Diagnostic Laboratory) Players and...
$ 3500